The latest clinical guidance from the American College of Physicians (ACP) marks a significant shift in how doctors treat menopausal symptoms. In a paper published in the Annals of Internal Medicine, the ACP recommends that women who suffer from hot flashes and night sweats receive estrogen‑progestogen therapy if they have a uterus, or estrogen alone if they have had a hysterectomy.
Why the change matters for families
For many families, menopausal symptoms can disrupt daily life, affecting mood, sleep quality and overall well‑being. The new recommendation aims to restore comfort and stability during this transition, helping women not only survive but thrive. By addressing these symptoms early, the guidelines also hope to reduce downstream health concerns that can strain families, such as cognitive decline.
Alternatives when hormones aren’t an option
Recognizing that hormone therapy may be contraindicated for some patients, the ACP outlines a clear hierarchy of second‑ and third‑line treatments. Selective serotonin‑norepinephrine reuptake inhibitors (SNRIs) are the preferred next step, followed by selective serotonin reuptake inhibitors (SSRIs), gabapentin, or newer neurokinin‑1 receptor antagonists such as elenzanetant and fezolinetant.
Potential link to dementia risk
A recent study in Nature Medicine identified 16 blood‑borne molecules that rise during menopause and correlate with brain‑aging processes. Higher levels of these markers were associated with an increased risk of dementia. While the research is still emerging, the ACP’s endorsement of hormone therapy suggests that managing menopausal symptoms could also help modulate these molecular changes, offering a proactive approach to long‑term brain health.
Practical steps for patients
Women experiencing severe hot flashes or night sweats should discuss the new recommendations with their gynecologist. Key considerations include:
- Confirming whether a uterus is present to determine the appropriate estrogen‑progestogen combination.
- Evaluating personal and family medical history for hormone‑related risks.
- Exploring low‑dose aspirin use alongside estrogen, as some clinicians suggest it may lower clotting risk.
- Considering alternative medications if hormone therapy is not suitable.
Beyond medication, lifestyle measures such as regular exercise, balanced nutrition, adequate sleep and stress management remain essential components of a healthy menopause transition.
Looking ahead
The ACP’s updated guidance reflects a broader movement in women’s health toward individualized, evidence‑based care. As more research clarifies the relationship between menopause, hormone therapy and cognitive health, clinicians expect to refine treatment pathways further. For now, the new recommendations provide a clear, supportive framework for women and their families seeking relief from disruptive menopausal symptoms.
Original reporting: Texarkana Gazette — read the source article.
